Abstract
Fractionated radiotherapy (FRT) and gamma knife stereotactic radiosurgery (GKSRS) are used as adjuvant therapies to surgical resection for functional and non-functional pituitary adenomas, although their optimum role in the treatment algorithm, as well as long-term safety and efficacy, still awaits further study. We report a single center experience with 33 patients with non-functional (16 patients), ACTH- (five patients), GH- (four patients), or prolactin-secreting (eight patients) tumors treated with FRT or SRS. The median tumor diameter was 1.9 cm, and the median follow-up was 36 months. For GKSRS, the median dosage was 16 Gy for non-functional adenomas and 23 Gy for hormone-secreting tumors. The median total dose for FRT was 50.4 Gy over 28 fractions (median). Two patients (6%) demonstrated radiographic evidence of tumor progression, three patients (9%) demonstrated radiation-induced visual field deficits on neuro-ophthalmic evaluation, and two patients (6%) suffered from radiation-induced hypopituitarism. Biochemical control, defined as normalized hormone values in the absence of medical therapy, was achieved in five out of eight prolactinoma patients and two out of five patients with Cushing’s disease, but none of the four patients with acromegaly. These results are presented with a review of the relevant literature on the differential characteristics of FRT versus SRS in the treatment of functional and non-functional pituitary adenomas and validate postoperative irradiation as a potentially safe and effective means for tumor control.
Similar content being viewed by others
References
Adler JR, Gibbs IC, Puataweepong P, Chang SD (2008) Visual field preservation after multisession Cyberknife radiosurgery for perioptic lesions. Neurosurgery 62:733–743
Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna S, Luton JP, Bertherat J (2000) Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 85:3779–3785
Biermasz N, van Dulken H, Roelfsema F (2000) Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 85:2476–2482
Castinetti F, Nagai M, Morange I, Dufour H, Caron P, Chanson P, Cortet-Rudelli C, Kuhn JM, Conte-Devolx B, Regis J, Brue T (2009) Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab 94:3400–3407
Chang EF, Zada G, Kim S, Lamborn KR, Quinones-Hinojosa A, Tyrrell JB, Wilson CB, Kunwar S (2008) Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg 108:736–745
Chen CC, Chapman P, Petit J, Loeffler J (2007) Proton radiosurgery in neurosurgery. Neurosurg Focus 23:E4
Estrada J, Boronat M, Mielgo M, Magallon R, Millan I, Diez S, Lucas T, Barcelo B (1997) The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. N Engl J Med 336:172–177
Feigl GC, Bonelli CM, Berghold A, Mokry M (2002) Effects of gamma knife radiosurgery of pituitary adenomas on pituitary function. J Neurosurg 97:415–421
Ghostine S, Ghostine MS, Johnson WD (2000) Radiation therapy in the treatment of pituitary tumors. Neurosurg Focus 24:E8
Hoybye C, Rahn T (2009) Adjuvant gamma knife radiosurgery in non-functioning pituitary adenomas; low risk of long-term complications in selected patients. Pituitary 12:211–216
Hoybye C, Grenbäck E, Rähn T, Degerblad M, Thorén M, Hulting AL (2001) Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery. Neurosurgery 49:284–292
Izawa M, Hayashi M, Nakaya K, Satoh H, Ochiai T, Hori T, Takakura K (2000) Gamma knife radiosurgery for pituitary adenomas. J Neurosurg 93:19–25
Izawa M, Chernov M, Hayashi M, Nakaya K, Kamikawa S, Kato K, Higa T, Ujiie H, Kasuya H, Kawamata T, Okada Y, Kubo O, Iseki H, Hori T, Takakura K (2007) Management and prognosis of cysts developed on long-term follow-up after gamma knife radiosurgery for intracranial arteriovenous malformations. Surg Neurol 68:400–406
Jagannathan J, Sheehan JP, Pouratian N, Laws ER, Steiner L, Vance ML (2007) Gamma knife surgery for Cushing’s disease. J Neurosurg 106:980–985
Jagannathan J, Sheehan J, Pouratian N, Laws EJ, Steiner L, Vance M (2008) Gamma knife radiosurgery for acromegaly: outcomes after failed transsphenoidal surgery. Neurosurgery 62:1262–1269
Kokubo M, Sasai K, Shibamoto Y, Aoki T, Oya N, Mitsumori M, Takahashi J, Hashimoto N, Hiraoka M (2000) Long-term results of radiation therapy for pituitary adenoma. J Neurooncol 47:79–84
Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, Wellis G (2000) Octreotide may act as a radioprotective agent in acromegaly. J Clin Endocrinol Metab 85:1287–1289
Laws EJ, Vance M (1999) Radiosurgery for pituitary tumors and craniopharyngiomas. Neurosurg Clin N Am 10:327–336
Liscak R, Vladyka V, Marek J, Simonova G, Vymazal J (2007) Gamma knife radiosurgery for endocrine-inactive pituitary adenomas. Acta Neurochir (Wien) 149:999–1006
Losa M, Valle M, Mortini P, Franzin A, di Passano CF, Cenzato M, Bianchi S, Picozzi P, Giovanelli M (2004) Gamma knife surgery for treatment of residual nonfunctioning pituitary adenomas after surgical debulking. J Neurosurg 100:438–443
Losa M, Gioia L, Picozzi P, Franzin A, Valle M, Giovanelli M, Mortini P (2008) The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab 93:2546–2552
Mahmoud-Ahmed A, Suh J (2002) Radiation therapy for Cushing’s disease: a review. Pituitary 5:175–80
Minniti G, Jaffrain-Rea M-L, Osti M, Esposito V, Santoro A, Solda F, Gargiulo P, Tamburrano G, Enrici R (2005) The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 62:210–216
Nishioka H, Hirano A, Haraoka J, Nakajima N (2002) Histological changes in the pituitary gland and adenomas following radiotherapy. Neuropathology 22:19–25
Paek SH, Downes MB, Bednarz G, Keane WM, Werner-Wasik M, Curran JWJ, Andrews DW (2005) Integration of surgery with fractionated stereotactic radiotherapy for treatment of nonfunctioning pituitary macroadenomas. Int J Radiat Oncol Biol Phys 61:795–808
Pamir MN, Kiliç T, Belirgen M, Abacioglu U, Karabekiroglu N (2007) Pituitary adenomas treated with gamma knife radiosurgery: volumetric analysis of 100 cases with minimum 3 year follow-up. Neurosurgery 61:270–280
Pollock BE, Carpenter PC (2003) Stereotactic radiosurgery as an alternative to fractionated radiotherapy for patients with recurrent or residual nonfunctioning pituitary adenomas. Neurosurgery 53:1086–1094
Pollock BE, Young WF (2002) Stereotactic radiosurgery for patients with ACTH-producing pituitary adenomas after prior adrenalectomy. Int J Radiat Oncol Biol Phys 54:839–841
Pollock BE, Jacob JT, Brown PD, Nippoldt TB (2007) Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg 106:833–836
Pollock BE, Brown P, Nippoldt T, Young WJ (2008) Pituitary tumor type affects the chance of biochemical remission after radiosurgery of hormone-secreting pituitary adenomas. Neurosurgery 62:1271–1276
Pollock BE, Cochran J, Natt N, Brown PD, Erickson D, Link MJ, Garces YI, Foote RL, Stafford SL, Schomberg PJ (2008) Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int J Radiat Oncol Biol Phys 70:1325–1329
Pouratian N, Sheehan J, Jagannathan J, Laws ER, Steiner L, Vance ML (2006) Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery 59:255–266
Sheehan JM, Vance ML, Sheehan JP, Ellegala DB, Laws ER (2000) Radiosurgery for Cushing’s disease after failed transsphenoidal surgery. J Neurosurg 93:738–740
Sheehan JP, Niranjan A, Sheehan JM, Jane JA, Laws ER, Kondziolka D, Flickinger J, Landolt AM, Loeffler JS, Lunsford LD (2005) Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg 102:678–686
Sheehan JP, Jagannathan J, Pouratian N, Steiner L (2006) Stereotactic radiosurgery for pituitary adenomas: a review of the literature and our experience. Front Horm Res 34:185–205
Stafford S, Pollock B, Leavitt J, Foote R, Brown P, Link M, Gorman D, Schomberg P (2003) A study on the radiation tolerance of the optic nerves and chiasm after stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 55:1177–1181
Vladyka V, Lišcák R, Novotný JJ, Marek J, Ježková J (2003) Radiation tolerance of functioning pituitary tissue in gamma knife surgery for pituitary adenomas. Neurosurgery 52:309–317
Zierhut D, Flentje M, Adolph J, Erdmann J, Raue F, Wannenmacher M (1995) External radiotherapy of pituitary adenomas. Int J Radiat Oncol Biol Phys 33:307–314
Acknowledgments
This work was supported in part by a grant from the Salisbury Foundation to DR.
Financial disclosure information
The authors in this manuscript have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Comments
Miguel A. Arraez, Malaga, Spain
This paper carries out the study of 33 patients that underwent radiotherapy treatment for invasive or recurrent pituitary adenoma. In the recurrent tumor, the mainstay of treatment in such a situation is radiotherapy once reoperation has been ruled out (sterotactic fraccionated radiotherapy or stereotactic radiosurgery). These modalities have different context in accordance to the volume and proximity to critical organs like optic pathways. Although this study lacks of a large number of cases and long follow-up, it depicts the usefulness of these modalities of stereotactic radiation to control pituitary adenomas. The figures of control are in full accordance with the previous published articles for non-secreting tumors. In secreting pituitary adenomas, a very acceptable rate of biochemical control has been obtained. Some figures are in disagreement to the previously published data regarding the cure of acromegaly patients but, as the authors also stated, a longer period is needed to properly assess the usefulness of radiation therapy in GH-secreting tumors. Another issue of interest is the possibility of radiation without previous surgery. In this series, it was done after rejection of the surgical treatment for the patients. Undoubtedly, the debate about the possibility of elective radiation arises as first choice treatment for selected cases. The potential toxicity should be also taken into account. The 10% figures of delayed optic damage must lead us to the reflection for appropriate case selection and modality of treatment. The possibility of hypopituitarism mustn’t be forgotten whose low figures in this series are also attributed to a short follow-up.
Francesco DiMeco, Ida Milanesi, Marcello Marchetti, Milan, Italy
Radiation therapy for pituitary adenomas is still a debated and controversial topic. Previous reports have shown that conventional radiation is effective in tumor growth control and hormonal normalization.
Radiosurgery, while limiting irradiation and potential damages to the normal tissue, raises concerns about possible post-treatment hypopituitarism and visual function worsening. In addition, it carries potential risks of hyatrogenic tumors development or cognitive function impairment. The present article tries to address these issues showing good results with acceptable side effects. However, higher powered studies with longer follow-up are needed in order to corroborate these findings.
Rights and permissions
About this article
Cite this article
Sun, D.Q., Cheng, J.J., Frazier, J.L. et al. Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature. Neurosurg Rev 34, 181–189 (2011). https://doi.org/10.1007/s10143-010-0285-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10143-010-0285-2